» Articles » PMID: 38201443

RSRC2 Expression Inhibits Malignant Progression of Triple-Negative Breast Cancer by Transcriptionally Regulating SCIN Expression

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Jan 11
PMID 38201443
Authors
Affiliations
Soon will be listed here.
Abstract

Triple-negative breast cancer (TNBC) has a shorter survival time and higher mortality rate than other molecular subtypes. RSRC2 is a newly discovered tumor suppressor gene. However, the potential functional mechanism of RSRC2 in TNBC remains unknown so far. Multiple bioinformatics databases were used. A Human Transcriptome Array 2.0 analysis, ChIP-seq analysis, ChIP-qPCR, RT-qPCR, Western blot, cell function assays in vitro and a metastatic mouse model in vivo were performed to demonstrate the role of RSRC2 in TNBC. Through the analysis of various databases, RSRC2 expression was the lowest in TNBC tissues compared to other molecular subtypes. The low expression of RSRC2 was associated with a worse prognosis for patients with breast cancer. The transcriptome array, ChIP-seq and bioinformatics analysis identified that GRHL2 and SCIN might have a close relationship with RSRC2. The functional bioinformatics enrichment analysis and functional cell experiments showed that RSRC2 was involved in cell adhesion, cell proliferation, cell migration and invasion. Furthermore, RSRC2 expression suppressed SCIN expression but not GRHL2 expression. SCIN re-expression in the RSRC2 overexpression cells or SCIN knockdown in the RSRC2 knockdown cells reversed the cellular function caused by RSRC2. Mechanistically, RSRC2 transcriptionally inhibited SCIN expression. In summary, our study reveals that RSRC2 acts as a tumor suppressor in TNBC development and progression through negatively regulating SCIN-mediated cell function, thus providing a potential target for TNBC treatment.

Citing Articles

Lnc-EST885 promotes hepatocellular carcinoma metastasis through PI3K / AKT pathway by interaction with TRAF4.

Zhu S, Wang G, Zhang Y, Zou M, Li Z, Qu S Transl Oncol. 2024; 52():102254.

PMID: 39721246 PMC: 11732567. DOI: 10.1016/j.tranon.2024.102254.

References
1.
Liu J, Liu J, Chen J, Wu Y, Yan P, Ji C . Scinderin promotes the invasion and metastasis of gastric cancer cells and predicts the outcome of patients. Cancer Lett. 2016; 376(1):110-7. PMC: 7832082. DOI: 10.1016/j.canlet.2016.03.035. View

2.
Zhang W, Liu R, Zhang L, Wang C, Dong Z, Feng J . Downregulation of miR-335 exhibited an oncogenic effect via promoting KDM3A/YAP1 networks in clear cell renal cell carcinoma. Cancer Gene Ther. 2021; 29(5):573-584. PMC: 9113937. DOI: 10.1038/s41417-021-00335-3. View

3.
Perilli L, Tessarollo S, Albertoni L, Curtarello M, Pasto A, Brunetti E . Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer. BMC Cancer. 2019; 19(1):821. PMC: 6700772. DOI: 10.1186/s12885-019-5982-9. View

4.
Carrigan P, Bingham J, Srinvasan S, Brentnall T, Miller L . Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer. Pancreas. 2010; 40(2):281-8. PMC: 3038180. DOI: 10.1097/MPA.0b013e31820128d2. View

5.
Xiang X, Liu Y, Kang Y, Lu X, Xu K . MEX3A promotes nasopharyngeal carcinoma progression via the miR-3163/SCIN axis by regulating NF-κB signaling pathway. Cell Death Dis. 2022; 13(4):420. PMC: 9056523. DOI: 10.1038/s41419-022-04871-0. View